keyword
MENU ▼
Read by QxMD icon Read
search

metformin non glycemic effect

keyword
https://www.readbyqxmd.com/read/27914133/lobeglitazone-a-novel-thiazolidinedione-improves-non-alcoholic-fatty-liver-disease-in-type-2-diabetes-its-efficacy-and-predictive-factors-related-to-responsiveness
#1
Yong Ho Lee, Jae Hyeon Kim, So Ra Kim, Heung Yong Jin, Eun Jung Rhee, Young Min Cho, Byung Wan Lee
Despite the rapidly increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes (T2D), few treatment modalities are currently available. We investigated the hepatic effects of the novel thiazolidinedione (TZDs), lobeglitazone (Duvie) in T2D patients with NAFLD. We recruited drug-naïve or metformin-treated T2D patients with NAFLD to conduct a multicenter, prospective, open-label, exploratory clinical trial. Transient liver elastography (Fibroscan®; Echosens, Paris, France) with controlled attenuation parameter (CAP) was used to non-invasively quantify hepatic fat contents...
January 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/27912784/liraglutide-improves-metabolic-parameters-and-carotid-intima-media-thickness-in-diabetic-patients-with-the-metabolic-syndrome-an-18-month-prospective-study
#2
Manfredi Rizzo, Ali A Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano, Stefano Genovese, Antonio Ceriello
BACKGROUND: Liraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM. METHODS: We performed an 18-month prospective, real-world study...
December 3, 2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27832864/impaired-adipose-tissue-lipid-storage-but-not-altered-lipolysis-contributes-to-elevated-levels-of-nefa-in-type-2-diabetes-degree-of-hyperglycemia-and-adiposity-are-important-factors
#3
Maria J Pereira, Stanko Skrtic, Petros Katsogiannos, Niclas Abrahamsson, Cherno O Sidibeh, Santosh Dahgam, Marianne Månsson, Ulf Risérus, Joel Kullberg, Jan W Eriksson
BACKGROUND: Elevated levels of circulating non-esterified fatty acids (NEFA) mediate many adverse metabolic effects. In this work we aim to determine the impact of type 2 diabetes (T2D), glycemic control and obesity on lipolysis regulation. DESIGN AND PARTICIPANTS: 20 control and 20 metformin-treated T2D subjects were matched for sex (10M/10 F), age (58±11 vs 58±9 y) and BMI (30.8±4.6 vs 30.7±4.9kg/m(2)). In vivo lipolysis was assessed during a 3h-OGTT with plasma glycerol and NEFA levels...
December 2016: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/27803118/adiponectin-insulin-sensitivity-%C3%AE-cell-function-and-racial-ethnic-disparity-in-treatment-failure-rates-in-today
#4
Silva Arslanian, Laure El Ghormli, Fida Bacha, Sonia Caprio, Robin Goland, Morey W Haymond, Lynne Levitsky, Kristen J Nadeau, Neil H White, Steven M Willi
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study demonstrated that glycemic failure rates in the three treatments combined-metformin plus rosiglitazone, metformin alone, and metformin plus lifestyle-were higher in non-Hispanic blacks (NHBs; 52.8%) versus non-Hispanic whites (NHWs; 36.6%) and Hispanics (Hs; 45.0%). Moreover, metformin alone was less effective in NHB versus NHW versus H youth. This study describes treatment-associated changes in adiponectin, insulin sensitivity, and β-cell function over time among the three racial/ethnic groups to understand potential mechanism(s) responsible for this racial/ethnic disparity...
November 1, 2016: Diabetes Care
https://www.readbyqxmd.com/read/27796904/strategies-for-diabetes-management-using-newer-oral-combination-therapies-early-in-the-disease
#5
REVIEW
Joel Zonszein, Per-Henrik Groop
INTRODUCTION: The duration of uncontrolled type 2 diabetes mellitus (T2DM) can adversely impact small and large vessels, eventually leading to microvascular and macrovascular complications. Failure of therapeutic lifestyle changes, monotherapy, and clinical inertia contribute to persistent hyperglycemia and disease progression. The aim was to review the complex pathophysiology of type 2 diabetes and how different oral agents can be used effectively as first-line therapy in combination with metformin, as well as in patients not achieving glycemic goals with metformin therapy...
December 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27762096/beneficial-effect-of-lixisenatide-after-76-weeks-of-treatment-in-patients-with-type-2-diabetes-mellitus-a-meta-analysis-from-the-getgoal-program
#6
Fabio Broglio, Edoardo Mannucci, Raffaele Napoli, Antonio Nicolucci, Francesco Purrello, Elena Nikonova, William Stager, Roberto Trevisan
AIMS: To evaluate long term efficacy and safety of lixisenatide, a short-acting, prandial GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonists) as add-on therapy in type 2 diabetes mellitus. METHODS: A meta-analysis of 76-week results of five placebo-controlled clinical trials from the GetGoal program was performed including 3,000 inadequately controlled adult diabetic patients where lixisenatide 20 µg once-daily was administered in combination with metformin (GetGoal-M and GetGoal-F1), sulphonylurea ± metformin (GetGoal-S), basal insulin ± metformin (GetGoal-L) or pioglitazone ± metformin (GetGoal-P)...
October 20, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27519177/metformin-use-and-its-effect-on-survival-in-diabetic-patients-with-advanced-non-small-cell-lung-cancer
#7
Oscar Arrieta, Edgar Varela-Santoyo, Enrique Soto-Perez-de-Celis, Roberto Sánchez-Reyes, Martha De la Torre-Vallejo, Saé Muñiz-Hernández, Andrés F Cardona
BACKGROUND: Previous population-based studies have demonstrated an association between metformin use and improved survival among diabetic patients with cancer. We sought to analyze the effects of diabetes and its treatment in terms of the survival of patients with lung cancer. METHODS: Overall, 1106 patients with non-small cell lung cancer (94.3 % with stage IV disease) were included. The outcomes were compared between the patients with (n = 186) and without diabetes (n = 920)...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27214299/metformin-non-glycemic-effects-and-potential-novel-indications
#8
Abeer Anabtawi, John M Miles
Metformin is the most commonly prescribed drug for the treatment of type 2 diabetes because of its apparent robust effects in reducing cardiovascular risk. The United Kingdom Prospective Diabetes Study suggests that metformin reduces the risk of myocardial infarction, and more recent retrospective studies have shown an association between metformin and a reduction in stroke, atrial fibrillation and all-cause mortality. The mechanism(s) explaining these putative benefits are not clear but may involve decreased energy intake (with attendant weight loss), improvement in lipids, and lowering of blood pressure; a review of selected literature suggests that metformin lowers blood pressure when it is elevated, but not when it is normal...
May 23, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27098505/comparison-of-vildagliptin-and-pioglitazone-in-korean-patients-with-type-2-diabetes-inadequately-controlled-with-metformin
#9
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim
BACKGROUND: We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes. METHODS: The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control...
June 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/27040861/safety-and-efficacy-of-dipeptidyl-peptidase-4-inhibitors-vs-sulfonylurea-in-metformin-based-combination-therapy-for-type-2-diabetes-mellitus-systematic-review-and-meta-analysis
#10
Naghmeh Foroutan, Sergei Muratov, Mitchell Levine
PURPOSE: The purpose of this study was to compare the safety and efficacy of DPP-4 inhibitors versus sulfonylurea as adjunctive second-line therapy in patients with type 2 diabetes mellitus, inadequately controlled with metformin mono-therapy. SOURCES: A systematic review of published randomized controlled trials (RCTs) was performed in MEDLINE, EMBASE, PubMed and Cochrane library. Two reviewers independently selected the studies, extracted the data and assessed the risk of bias...
2016: Clinical and Investigative Medicine. Médecine Clinique et Experimentale
https://www.readbyqxmd.com/read/26933918/practical-considerations-for-the-use-of-sodium-glucose-co-transporter-type-2-inhibitors-in-treating-hyperglycemia-in-type-2-diabetes
#11
Karen S L Lam, Chun Chung Chow, Kathryn C B Tan, Ronald C W Ma, Alice P S Kong, Peter C Y Tong, Man Wo Tsang, Tak Mao Chan, Sydney C W Tang, Ka Kui Lee, Wing Yee So, Brian Tomlinson
Sodium-glucose co-transporter type 2 (SGLT2) inhibitors are a new class of oral anti-diabetic agents with a unique, insulin-independent mode of action. In patients with diabetes who have adequate renal function, SGLT2 inhibitors reduce hyperglycemia by blocking renal glucose reabsorption and increasing urinary glucose excretion. These agents are indicated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM), as an adjunct to diet and exercise. In terms of efficacy, they are comparable to most other oral agents, and carry a low risk of hypoglycemia unless combined with sulfonylureas or insulin...
June 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/26796432/diabetes-medications-impact-on-inflammation-and-wound-healing
#12
REVIEW
Jay J Salazar, William J Ennis, Timothy J Koh
Chronic wounds are a common complication in patients with diabetes that often lead to amputation. These non-healing wounds are described as being stuck in a persistent inflammatory state characterized by accumulation of pro-inflammatory macrophages, cytokines and proteases. Some medications approved for management of type 2 diabetes have demonstrated anti-inflammatory properties independent of their marketed insulinotropic effects and thus have underappreciated potential to promote wound healing. In this review, the potential for insulin, metformin, specific sulfonylureas, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors to promote healing is evaluated by reviewing human and animal studies on inflammation and wound healing...
May 2016: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/26762150/effect-of-a-patient-decision-aid-pda-for-type-2-diabetes-on-knowledge-decisional-self-efficacy-and-decisional-conflict
#13
RANDOMIZED CONTROLLED TRIAL
Robert A Bailey, Michael Pfeifer, Alicia C Shillington, Qing Harshaw, Martha M Funnell, Jeffrey VanWingen, Nanada Col
BACKGROUND: Patients with type 2 diabetes (T2DM) often have poor glycemic control on first-line pharmacologic therapy and require treatment intensification. Intensification decisions can be difficult because of many available options and their many benefits and risks. The American Diabetes Association recommends patient-centered, evidence-based tools supporting shared decision-making between patients and clinicians. We developed a patient decision aid (PDA) targeting decisions about treatment intensification for T2DM...
January 14, 2016: BMC Health Services Research
https://www.readbyqxmd.com/read/26592507/insulin-resistance-role-of-metformin-and-other-non-insulin-therapies-in-pediatric-type-1-diabetes
#14
Fida Bacha, Sara Klinepeter Bartz
Type 1 diabetes mellitus (T1DM) in youth is a challenging chronic medical condition. Its management should address not only the glycemic control but also insulin resistance and cardiovascular disease risk factors which are increasingly recognized to be present in youth with TID. Current knowledge on the mechanisms of insulin resistance in T1DM is reviewed. The use of adjunctive therapies that are beneficial to achieve adequate glycemic control while mitigating the effects of insulin resistance are discussed with a focus on metformin therapy and an overview of other new pharmacologic agents...
November 23, 2015: Pediatric Diabetes
https://www.readbyqxmd.com/read/26480253/-anti-diabetics-and-chronic-kidney-disease
#15
Carlo Garofalo, Nicolangelo Iazzetta, Andrea Camocardi, Mario Pacilio, Carmela Iodice, Roberto Minutolo, Luca De Nicola, Giuseppe Conte
Diabetes mellitus (DM) is the most important non-communicable disease after hypertension. Prevalence of type 2 DM has progressively increased over the last decades. In Italy, 11.8% of the general adult population can be identified as diabetic. The major complication of DM is diabetic nephropathy (DM-CKD), which develops in approximately one-third of diabetics. Achieving optimal glycemic control is the first therapeutic goal in the management of DM-CKD. In recent years, new antidiabetic drugs have been marketed (GLP1 analogues, DPP-4 inhibitors, SGLT-2 inhibitors) to ameliorate glycemia in patients nave or treated by means of traditional agents, such as sulfonylureas, metformin, glinides, insulin...
September 2015: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/26414434/canagliflozin-treatment-of-hispanic-and-non-hispanic-patients-with-type-2-diabetes-in-a-us-managed-care-setting
#16
Wing Chow, Erin Buysman, Marcia F T Rupnow, Richard Aguilar, Henry J Henk
BACKGROUND: Hispanic/Latino (H/L) ethnicity is associated with higher prevalence of type 2 diabetes mellitus (T2DM) and more complications and comorbidities. Few studies of antihyperglycemic agents (AHAs) have compared H/L with non-H/L patients. Randomized controlled trials and observational studies have shown canagliflozin (CANA) is effective at lowering hemoglobin A1C (A1C). OBJECTIVE: To describe characteristics and compare glycemic control between H/L and non-H/L patients with T2DM filling their first prescription for CANA...
2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/26367281/a-randomized-double-blind-placebo-controlled-trial-of-adjunctive-metformin-therapy-in-overweight-obese-youth-with-type-1-diabetes
#17
RANDOMIZED CONTROLLED TRIAL
Benjamin Udoka Nwosu, Louise Maranda, Karen Cullen, Lisa Greenman, Jody Fleshman, Nancy McShea, Bruce A Barton, Mary M Lee
CONTEXT: Insulin resistance has been proposed as one of the causes of poor glycemic control in overweight/obese youth with type 1 diabetes (T1D). However, the role of adjunctive metformin, an insulin sensitizer, on glycemic control in these patients is unclear. OBJECTIVE: To compare the effect of metformin vs. placebo on hemoglobin A1c (HbA1c), total daily dose (TDD) of insulin, and other parameters in overweight/obese youth with T1D. HYPOTHESIS: Adjunctive metformin therapy will improve glycemic control in overweight/obese youth with T1D...
2015: PloS One
https://www.readbyqxmd.com/read/26366205/probiotic-b420-and-prebiotic-polydextrose-improve-efficacy-of-antidiabetic-drugs-in-mice
#18
Lotta K Stenman, Aurélie Waget, Céline Garret, François Briand, Rémy Burcelin, Thierry Sulpice, Sampo Lahtinen
BACKGROUND: Gut microbiota is now known to control glucose metabolism. Previous studies have shown that probiotics and prebiotics may improve glucose metabolism, but their effects have not been studied in combination with drug therapy. The aim of this study was to investigate whether probiotics and prebiotics combined with drug therapy affect diabetic outcomes. METHODS: Two different study designs were used to test gut microbiota modulating treatments with metformin (MET) or sitagliptin (SITA) in male C57Bl/6J mice...
2015: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/26312070/twelve-week-randomized-study-to-compare-the-effect-of-vildagliptin-vs-glibenclamide-both-added-on-to-metformin-on-endothelium-function-in-patients-with-type-2-diabetes-and-hypertension
#19
Luciana Neves Cosenso-Martin, Luiz Tadeu Giollo-Júnior, Débora Dada Martineli, Cláudia Bernardi Cesarino, Marcelo Arruda Nakazone, José Paulo Cipullo, José Fernando Vilela-Martin
BACKGROUND: Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to evaluate the effect of vildagliptin on endothelial function and arterial stiffness in patients with T2DM and hypertension. METHODS: Fifty over 35-year-old patients with T2DM and hypertension, without cardiovascular disease, will be randomly allocated to two groups: group 1 will receive vildagliptin added-on to metformin and group 2, glibenclamide added-on to metformin...
2015: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/26117686/metformin-for-the-treatment-of-gestational-diabetes-an-updated-meta-analysis
#20
REVIEW
Pimprapa Kitwitee, Supon Limwattananon, Chulaporn Limwattananon, Ornanong Waleekachonlert, Tananan Ratanachotpanich, Mattabhorn Phimphilai, Tuan V Nguyen, Chatlert Pongchaiyakul
OBJECTIVE: To assess the efficacy of metformin and insulin in the treatment of pregnant women with gestational diabetes mellitus (GDM). METHODS: A meta-analysis was conducted by including randomized controlled trials comparing metformin and insulin in GDM. An electronic search was conducted to identify relevant studies. Data were synthesized by a random effects meta-analysis model. A Bayesian analysis was also performed to account for uncertainties in the treatment efficacy...
September 2015: Diabetes Research and Clinical Practice
keyword
keyword
113374
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"